Logo image of XOMAO

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock Price, Quote, News and Overview

NASDAQ:XOMAO - Nasdaq - US98419J4040 - Currency: USD

25.151  +0.15 (+0.6%)

XOMAO Quote, Performance and Key Statistics

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

NASDAQ:XOMAO (5/5/2025, 8:00:03 PM)

25.151

+0.15 (+0.6%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High25.87
52 Week Low23.32
Market Cap300.55M
Shares11.95M
Float11.86M
Yearly Dividend0.47
Dividend Yield8.38%
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13
IPO06-06 1986-06-06


XOMAO short term performance overview.The bars show the price performance of XOMAO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -0.5 -1 -1.5

XOMAO long term performance overview.The bars show the price performance of XOMAO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 2 4 6

The current stock price of XOMAO is 25.151 USD. In the past month the price increased by 0.12%. In the past year, price increased by 0.2%.

XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO Daily stock chart

XOMAO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.09 346.84B
AMGN AMGEN INC 13.49 150.57B
VRTX VERTEX PHARMACEUTICALS INC 1724.79 128.59B
GILD GILEAD SCIENCES INC 13.28 128.00B
REGN REGENERON PHARMACEUTICALS 13.62 65.17B
ARGX ARGENX SE - ADR 345.61 40.09B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.58B
ONC BEIGENE LTD-ADR N/A 27.40B
BNTX BIONTECH SE-ADR N/A 24.30B
NTRA NATERA INC N/A 21.40B
SMMT SUMMIT THERAPEUTICS INC N/A 20.81B
BIIB BIOGEN INC 7.7 17.85B

About XOMAO

Company Profile

XOMAO logo image XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others.

Company Info

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

2200 Powell Street, Suite 310

Emeryville CALIFORNIA US

Employees: 13

XOMAO Company Website

XOMAO Investor Relations

Phone: 15102047239

XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO FAQ

What is the stock price of XOMA ROYALTY CORP - XOMA 8 3/8 PERP today?

The current stock price of XOMAO is 25.151 USD. The price increased by 0.6% in the last trading session.


What is the ticker symbol for XOMA ROYALTY CORP - XOMA 8 3/8 PERP stock?

The exchange symbol of XOMA ROYALTY CORP - XOMA 8 3/8 PERP is XOMAO and it is listed on the Nasdaq exchange.


On which exchange is XOMAO stock listed?

XOMAO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for XOMA ROYALTY CORP - XOMA 8 3/8 PERP stock?

10 analysts have analysed XOMAO and the average price target is 71.92 USD. This implies a price increase of 185.97% is expected in the next year compared to the current price of 25.151. Check the XOMA ROYALTY CORP - XOMA 8 3/8 PERP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is XOMA ROYALTY CORP - XOMA 8 3/8 PERP worth?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a market capitalization of 300.55M USD. This makes XOMAO a Small Cap stock.


How many employees does XOMA ROYALTY CORP - XOMA 8 3/8 PERP have?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) currently has 13 employees.


What are the support and resistance levels for XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a support level at 25.14 and a resistance level at 25.21. Check the full technical report for a detailed analysis of XOMAO support and resistance levels.


Is XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) expected to grow?

The Revenue of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is expected to grow by 15.45% in the next year. Check the estimates tab for more information on the XOMAO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock pay dividends?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a dividend yield of 8.38%. The yearly dividend amount is currently 0.47. Check the full fundamental report for a detailed analysis of XOMAO dividend history, reliability and sustainability.


When does XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) report earnings?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) will report earnings on 2025-05-13.


What is the Price/Earnings (PE) ratio of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO)?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.06).


What is the Short Interest ratio of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

The outstanding short interest for XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is 0.04% of its float. Check the ownership tab for more information on the XOMAO short interest.


XOMAO Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to XOMAO. When comparing the yearly performance of all stocks, XOMAO turns out to be only a medium performer in the overall market: it outperformed 56.9% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

XOMAO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to XOMAO. Both the profitability and financial health of XOMAO have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XOMAO Financial Highlights

Over the last trailing twelve months XOMAO reported a non-GAAP Earnings per Share(EPS) of -2.06. The EPS increased by 4.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -11.87%
ROE -32.06%
Debt/Equity 1.3
Chartmill High Growth Momentum
EPS Q2Q%8.16%
Sales Q2Q%375.4%
EPS 1Y (TTM)4.63%
Revenue 1Y (TTM)529.37%

XOMAO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to XOMAO. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 72.39% and a revenue growth 15.45% for XOMAO


Ownership
Inst Owners61.19%
Ins Owners0.87%
Short Float %0.04%
Short Ratio1.38
Analysts
Analysts82
Price Target71.92 (185.95%)
EPS Next Y72.39%
Revenue Next Year15.45%